期刊
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 16
卷 16, 期 -, 页码 347-370出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-bioeng-071813-105119
关键词
siRNA delivery; nanoparticle; gene therapy; stability; intracellular trafficking
资金
- NCI NIH HHS [U54CA151838] Funding Source: Medline
- NHLBI NIH HHS [HL109442] Funding Source: Medline
- NIAID NIH HHS [AI096395] Funding Source: Medline
- NIBIB NIH HHS [EB015000, EB013274-01A1, EB015152] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [U54CA151838] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL109442] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB015152, R21EB013274] Funding Source: NIH RePORTER
Inhibiting specific gene expression by short interfering RNA (siRNA) offers a new therapeutic strategy to tackle many diseases, including cancer, metabolic disorders, and viral infections, at the molecular level. The macromolecular and polar nature of siRNA hinders its cellular access to exert its effect. Nanoparticulate delivery systems can promote efficient intracellular delivery. Despite showing promise in many preclinical studies and potential in some clinical trials, siRNA has poor delivery efficiency, which continues to demand innovations, from carrier design to formulation, in order to overcome transport barriers. Previous findings for optimal plasmid DNA delivery cannot be generalized to siRNA delivery owing to significant discrepancy in size and subtle differences in chain flexibility between the two types of nucleic acids. In this review, we highlight the recent advances in improving the stability of siRNA nanoparticles, understanding their intracellular trafficking and release mechanisms, and applying judiciously the promising formulations to disease models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据